Member Info for Richob

...are suing Pfizer and Biontech over vaccines.

Is it us?

Onwards Avacta.

Onwards! Close though!

I agree with 0 part but think this will be well before when the trial moves to the various solid tumour part, which we already know is being recruited for.

You could add another 0 for "ex China".

Onwatds Avacta.

Nicholas 70. Just read your previous posts.

What on earth are still doing here?

Onwards Avacta.

The original patents were jointly filed:

https://avacta.com/major-therapeutics-co-development-partnership/

Don't see that this has changed. Do see that the timing seems relative to AVA600O.

Onwards Avacta.

From the 2018 collaboration agreement:

Avacta and Tufts have jointly filed for broad patent protection for this inventive concept. The patent covers Affimers, and a wide range of other binders, against oncology, viral and inflammatory targets that are not internalised rapidly enough to be useful in traditional antibody-drug conjugates. It also covers a wide range of drugs to which the binders can be conjugated.

I think Alistair knows his onions as well.

The 2018 collaboration is well worth a read.

All lining up me thinks.

Onwards Avacta.

From July 2018:

https://avacta.com/major-therapeutics-co-development-partnership/

Onwards Avacta.

Unless I am reading the 29th June RNS incorrectly, the trial is about improving the therapeutic index and consequently the lives of the patients.

Twice as good sounds like a great improvement. I can't imagine what 1000 times as good would be classed as but what an incredibly massive help that would be for patients worldwide.

Onwards Avacta.

Great find, gmcc.

The therapeutic index is a quantitative measurement of the relative safety of a drug. It is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity.

Looking at the improvements those numbers are saying is absolutely phenomenal.

Onwards Avacta.

They are not actually disclosing targets for Canseek at this time.

What we do know is that Avacta receive $9.5m for achieving the first target, $8.5m for each subsequent target plus royalties on future sales.

Nice little earners going forward I would say.

Onwards Avacta.

... and counting.

Plus anything else in the meantime.

Onwards Avacta.

So definitely involved with the collaboration with Point:

https://www.lse.co.uk/rns/AVCT/license-agreement-with-point-biopharma-inc-4ltd3yd383pyl32.html

Makes the current Point presentation a bit more interesting then.

Onwards Avacta.

This chap now works for Point.

Looks like he has previously worked for Avacta.

Might make the collaboration with Point a bit more understandable as their Canseek IP is licensed from Avacta and Dr Bachovin.

Onwards Avacta.

No worries, doctor11.

I just find it amazing that we have a collaboration worth four times the current market cap in addition to other collaborations and AVA6000.

From a potential take over perspective, one billion is about £5 per share, which could be recouped from the LG Chem collaboration alone. Hence higher figures are mentioned with regard to takeovers.

Onwards Avacta.

Apologies. I think I posted a couple of weeks ago that this collaboration was worth up to half a billion dollars.

Just found this from the time of the agreement and it looks like I might have been up to half a billion dollars out:

https://www.businessweekly.co.uk/news/biomedtech/thanks-billion-lg-chem-broadens-deal-avacta

Sorry.

Onwards Avacta.

... about Point is that it is one of a number of income generating ( up front plus royalties) collaborations.

gmcc has already mentioned LG Chem, which is probably the largest income contributor but there are more.

None of these relate directly (currently) to AVA 6000, which is Avacta's alone.

Some of the posts on here clearly avoid/deflect from "the point".

Some of the posts are clearly pointless.

Onwards Avacta.

Hiya, gmcc,

Thanks for your posts. The Mersana numbers show what large pharmas are prepared to pay for the IP of smaller companies and Avacta has some incredible IP.

I don't doubt that most people also don't appreciate the LG Chem deal that you also posted on, which is still worth twice the current market cap of Avacta and which undoubtedly more than pays running costs ( plus royalties to boot).

Not sure that many are looking beyond AVA6000, which is of blockbuster potential of course.

Have posted after close to avoid being accused of ramping !

All the best.

Onwards Avacta.

Hiya, gmcc,

Following your LG Chem initial post, I have been digging but not found much:

a) It says Oncology, so is cancer related.
b) Affimer technology is involved.
c) The latest RNS is about PDL-1 inhibitor and XT serum half life extension.
d) This triggered a $2m dollar payment.

So, looks like some form of cancer related treatment where the drug circulates longer due to the affimer XT half life extension being readied for clinical trials.

What remains patently clear (to me) is that the LG Chem contract is worth up to $450m to Avacta, which is twice the current valuation of Avacta and excludes:

1) AVA6000
2) AVA3996
3) The remainder of the AVA pipeline
4) TMAC
5) Affyxell
6) Daewoong
7) Point Biopharma
8) All other collaborations
9) Diagnostics

I'm sure that I am not alone in thinking we are very undervalued even if we only count LG Chem in the calculations.

Thanks again for your original find.

Onwards Avacta.

Nice link, gmcc.

This collaboration with LG Chem is worth $450m to Avacta, which is more than the company is currently valued at. Says it all really.

Thanks again.

Onwards Avacta.

What is your problem?

You've previously had a go at Timster. You have posted at prices lower than today's and yet claim you don't understand and are a long term holder and that we all wish we had as many shares as you.

For the record, Avacta has a number of opportunites:

AVA6000
The AVA pipeline
The LG Chem collaboration
Affyxell
Diagnostics

Whilst I could go on, I think you either believe that there is enough to make this a worthwhile investment or you don't.

Going on any about daily share price fluctuations is a bit like paranoia. How many people do you think know about Avacta. Fifty? A hundred? There are many people that wont have a clue.

Do you have a real question to ask?

Good luck to you.

Onwards Avacta.